T R Chauncey
Overview
Explore the profile of T R Chauncey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
946
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chauncey T
Turk J Haematol
. 2016 Jun;
17(4):155-62.
PMID: 27263632
Drug resistance markers are often predictive of treatment response and outcome in patients with acute myeloid leukemia. The immunologic detection of drug efflux pumps such as P-glycoprotein (Pgp) and multidrug...
2.
Bensinger W, Becker P, Gooley T, Chauncey T, Maloney D, Gopal A, et al.
Bone Marrow Transplant
. 2015 Sep;
51(1):67-71.
PMID: 26367217
We aimed to examine whether doses of melphalan higher than 200 mg/m(2) improve response rates when used as conditioning before autologous transplant (ASCT) in multiple myeloma (MM) patients. Patients with...
3.
Graf S, Stevenson P, Holmberg L, Till B, Press O, Chauncey T, et al.
Ann Oncol
. 2015 Sep;
26(11):2323-8.
PMID: 26347113
Background: High-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes for patients with mantle cell lymphoma (MCL), but relapse ultimately occurs in most patients. Recently presented interim results from...
4.
Scott B, Sandmaier B, Storer B, Maris M, Sorror M, Maloney D, et al.
Leukemia
. 2005 Nov;
20(1):128-35.
PMID: 16270037
Transplant outcome was analyzed in 150 patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia transformed from MDS (tAML) conditioned with nonmyeloablative or myeloablative regimens. A total of 38 patients...
5.
Kerbauy F, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali H, et al.
Leukemia
. 2005 Apr;
19(6):990-7.
PMID: 15800667
A total of 24 patients (median age 58; range, 27-71 years) with chronic myeloid leukemia (CML) in first chronic (CP1) (n=14), second chronic (n=4), or accelerated phase (n=6) who were...
6.
Baron F, Maris M, Storer B, Sandmaier B, Panse J, Chauncey T, et al.
Leukemia
. 2005 Mar;
19(5):822-8.
PMID: 15772701
This report examines the impact of graft composition on outcomes in 130 patients with hematological malignancies given unrelated donor granulocyte-colony-stimulating-factor-mobilized peripheral blood mononuclear cells (G-PBMC) (n = 116) or marrow...
7.
Panse J, Heimfeld S, Guthrie K, Maris M, Maloney D, Baril B, et al.
Br J Haematol
. 2005 Feb;
128(5):659-67.
PMID: 15725088
We have studied the influence of cell subsets [CD34, CD3, CD4, CD8, CD14, CD20, natural killer (NK; CD3(-)/CD56(+)), NKT (CD3(+)/CD56(+)), DC1, and DC2 cells] of granulocyte colony-stimulating factor mobilized peripheral...
8.
Zaucha J, Gooley T, Bensinger W, Heimfeld S, Chauncey T, Zaucha R, et al.
Blood
. 2001 Nov;
98(12):3221-7.
PMID: 11719357
A retrospective analysis of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cell (G-PBMC) products harvested from healthy donors indicates significant variability in both the absolute number and relative proportion of...
9.
McSweeney P, Niederwieser D, Shizuru J, Sandmaier B, Molina A, Maloney D, et al.
Blood
. 2001 May;
97(11):3390-400.
PMID: 11369628
Toxicities have limited the use of allogeneic hematopoietic cell transplantation (HCT) to younger, medically fit patients. In a canine HCT model, a combination of postgrafting mycophenolate mofetil (MMF) and cyclosporine...
10.
Anderson J, Appelbaum F, Schoch G, Barnett T, Chauncey T, Flowers M, et al.
Biol Blood Marrow Transplant
. 2001 Apr;
7(3):163-70.
PMID: 11302550
Patients with the refractory anemia (RA) subtype of myelodysplastic syndrome who undergo allogeneic bone marrow transplantation (BMT) have a low risk of relapse, but they have a high risk of...